Pelvic inflammatory disease in the People's Republic of China: aetiology and management.

Shang Hong; Chen Xin; Ye Qianhong; Wang Yanan; Xu Wenyan; Rosanna W Peeling ORCID logo; David Mabey ORCID logo; (2002) Pelvic inflammatory disease in the People's Republic of China: aetiology and management. International journal of STD & AIDS, 13 (8). pp. 568-572. ISSN 0956-4624 DOI: 10.1258/095646202760159710
Copy

OBJECTIVES: To study the causes of pelvic inflammatory disease (PID) in Shenyang, Northeastern China, and to assess the efficacy of the syndromic management flowchart for PID recommended by World Health Organization (WHO). METHODS: 200 outpatients with PID attending Gynaecologic Clinic of No. 1 and No. 2 hospital of China Medical University in Shenyang, and 155 control women without symptoms underwent pelvic examination, and were tested for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma hominis (MH), bacterial vaginosis (BV), Candida albicans (CA) and Trichomonas vaginalis (TV). RESULTS: In PID patients, the prevalence of MH was 26%, of BV 26%, of CT 16%, of CA 11%, of TV 4% and of NG 2.5%. In the control population, prevalences were 5.2%, 8.4%, 0%, 5.2%, 0.7%, 0% respectively. MH, BV and CT were significantly more common in PID patients than in controls (P<0.01). One hundred and thirty-seven of the 200 patients with PID (68.5%) returned for follow-up. Symptoms had resolved completely in 64 (47%), and had improved in 68 (50%). There was no improvement in five (4%). CONCLUSIONS: The management protocol for female lower abdominal pain recommended by WHO is effective in this setting.
Item Type Article
Keywords *Pelvic Inflammatory Disease/di [Diagnosis], *Pelvic Inflammatory Disease/dt [Drug Therapy], *Pelvic Inflammatory Disease/et [Etiology], Clinical Protocol, Clinical Examination, China, World Health Organization, Antibiotic Therapy, Chlamydia Trachomatis, Neisseria Gonorrhoeae, Mycoplasma Hominis, Vaginitis/di [Diagnosis], Vaginitis/dt [Drug Therapy], Vaginitis/et [Etiology], Candida Albicans, Trichomonas Vaginalis, Follow Up, Human, Female, Major Clinical Study, Controlled Study, Adult, Article, Priority Journal, Ceftriaxone/do [Drug Dose], Ceftriaxone/dt [Drug Therapy], Ceftriaxone/im [Intramuscular Drug Administration], Doxycycline/do [Drug Dose], Doxycycline/dt [Drug Therapy], Doxycycline/po [Oral Drug Administration], Metronidazole/do [Drug Dose], Metronidazole/dt [Drug Therapy], Metronidazole/po [Oral Drug Administration], 73384-59-5, 74578-69-1 (ceftriaxone). 10592-13-9, 17086-28-1, 564-25-0 (doxycycline). 39322-38-8, 443-48-1 (metronidazole), Adult, Animal, Candida albicans, isolation & purification, Case-Control Studies, China, epidemiology, Chlamydia trachomatis, isolation & purification, Female, Human, Middle Age, Mycoplasma hominis, isolation & purification, Neisseria gonorrhoeae, isolation & purification, Pelvic Inflammatory Disease, drug therapy, epidemiology, etiology, microbiology, Prevalence, Support, Non-U.S. Gov't, Trichomonas vaginalis, isolation & purification, Vaginosis, Bacterial, complications, microbiology

Explore Further

Full text not available from this repository.

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads